120 related articles for article (PubMed ID: 25439683)
1. Length of chemotherapy and use of bevacizumab for breast cancer.
Brufsky A
Lancet Oncol; 2014 Nov; 15(12):1285-7. PubMed ID: 25439683
[No Abstract] [Full Text] [Related]
2. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
3. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Miles D; Zielinski C; Martin M; Vrdoljak E; Robert N
Eur J Cancer; 2012 Mar; 48(4):482-91. PubMed ID: 22257791
[TBL] [Abstract][Full Text] [Related]
4. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Lück HJ; Lübbe K; Reinisch M; Maass N; Feisel-Schwickardi G; Tomé O; Janni W; Aydogdu M; Neunhöffer T; Ober A; Aktas B; Park-Simon TW; Schumacher C; Höffkes HG; Illmer T; Wagner H; Mehta K; von Minckwitz G; Nekljudova V; Loibl S
Breast Cancer Res Treat; 2015 Jan; 149(1):141-9. PubMed ID: 25519041
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer: combining bevacizumab with chemotherapy--from maintenance to second-line treatment.
Errico A
Nat Rev Clin Oncol; 2014 Nov; 11(11):621. PubMed ID: 25311354
[No Abstract] [Full Text] [Related]
6. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Bisagni G; Musolino A; Panebianco M; De Matteis A; Nuzzo F; Ardizzoni A; Gori S; Gamucci T; Passalacqua R; Gnoni R; Moretti G; Boni C
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1051-7. PubMed ID: 23377310
[TBL] [Abstract][Full Text] [Related]
7. Looking for predictive markers in breast cancer.
Bonotto M; Fontanella C; Puglisi F
Lancet Oncol; 2015 Jan; 16(1):e1. PubMed ID: 25638542
[No Abstract] [Full Text] [Related]
8. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
9. Looking for predictive markers in breast cancer--authors' reply.
Gligorov J
Lancet Oncol; 2015 Jan; 16(1):e1-2. PubMed ID: 25638543
[No Abstract] [Full Text] [Related]
10. San Antonio Breast Cancer Symposium.
Collingridge D
Lancet Oncol; 2008 Jan; 9(1):14. PubMed ID: 18183661
[No Abstract] [Full Text] [Related]
11. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in breast cancer: fundamental questions remain.
Miles DW
Lancet Oncol; 2013 Feb; 14(2):99-101. PubMed ID: 23369679
[No Abstract] [Full Text] [Related]
14. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Greil R; Moik M; Reitsamer R; Ressler S; Stoll M; Namberger K; Menzel C; Mlineritsch B
Eur J Surg Oncol; 2009 Oct; 35(10):1048-54. PubMed ID: 19250795
[TBL] [Abstract][Full Text] [Related]
15. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF
J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401
[No Abstract] [Full Text] [Related]
16. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Farkouh A; Scheithauer W; Buchner P; Georgopoulos A; Schueller J; Gruenberger B; Czejka M
Anticancer Res; 2014 Jul; 34(7):3669-73. PubMed ID: 24982385
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for advanced colorectal cancer--more is not always better.
Mayer RJ
N Engl J Med; 2009 Feb; 360(6):623-5. PubMed ID: 19196680
[No Abstract] [Full Text] [Related]
19. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Gajria D; Feigin K; Tan LK; Patil S; Geneus S; Theodoulou M; Norton L; Hudis CA; Traina TA
Cancer; 2011 Sep; 117(18):4125-31. PubMed ID: 21387266
[TBL] [Abstract][Full Text] [Related]
20. [Optimal chemotherapy for advanced and recurrent breast cancer patients].
Masuda N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():523-9. PubMed ID: 17682205
[No Abstract] [Full Text] [Related]
[Next] [New Search]